Literatur

• Literatur

• 1 Airaksinen EM. et al. A population-based study on epilepy in mentally retarded children. Epilepsia 2000; 41: 1214-1220.
• 2 Alvarez N. Epilepsy in children with mental retardiation. http://www.emedicine.com/NEURO/topic 550.htm (last updated: Aug 29, 2007).
• 3 Alvarez N, Besag F, Iivanainen M. Use of antiepileptic drugs in the treatment of epilepsy with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl. 01) 1-15.
• 4 Alvestad S, Lydersen St, Brodtkorb E. Rash from antiepileptic drugs : Influence by gender, age, and learning. Epilepsia 2007; 48: 1360-1365.
• 5 Arif H. et al. Comparison of antiepileptic drug oneyear retention rates in patients with epilepsy and mental retardation. Neurology 2007; 68 (Suppl. 01) A122.
• 6 Arroyo S. Rufinamide. Neurotherapeutics 2007; 04: 155-162.
• 7 Association for Methodology and Documentation in Psychiatry (AMDP), Collegium Internationale Psychiatriae Scalarum (CIPS). Rating scales for psychiatry. European ed. Weinheim: Beltz Test GmbH; 1990
• 8 Bauer J. Epilepsietherapie im Erwachsenenalter. Nervenarzt 2007; 78 (Suppl. 01) 27-35.
• 9 Baulac M. Introduction to zonisamide. Epilepsy Res 2006; 68S: S3-S9.
• 10 Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane database of systematic reviews 2007; 4.
• 11 Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial onset seizures. Drugs Today 2008; 44: 35-40.
• 12 Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12: 131-135.
• 13 Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998; 39: 280-282.
• 14 Besag FMC. Lamotrigine in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl. 01) 50-56.
• 15 Bhaumik S. et al. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 1997; 06: 127-133.
• 16 Brodtkorb E, Sand T, Strandjord RE. Neuroleptic and antiepileptic treatment in the mentally retarded. Seizure 1993; 02: 205-211.
• 17 Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995; 04: 233-236.
• 18 Bundschuh K. Testtheoretische und methodische Fragen der Diagnostik. In: Stahl B, Irblich D. (Hrsg). Diagnostik bei Menschen mit geistiger Behinderung. Göttingen: Hogrefe; 2005: 30-48.
• 19 Callaghan BC. et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382-389.
• 20 Chahem J, Bauer J. Epilepsietherapie mit Antiepileptika der dritten Wahl – Felbamat, Tiagabin und Sultiam. Nervenarzt 2007; 78: 1407-1412.
• 21 Chiron C. Stiripentol. Neurotherapeutics 2007; 04: 123-125.
• 22 Chmielewska B, Stelmasiak Z. Effectiveness of adjunctive therapy with tiagabine in mentally disabled patients with epilepsy. Ann Univ Mariae Curie Sklodowska (Med) 2002; 57: 226-236.
• 23 Coppola G. et al. Topiramate in children and adolescents with epilepsy and mental retardation: a propective study on behavior and cognitive effects. Epilepsy Behav 2008; 12: 253-256.
• 24 Deb S, Siani STK. Levetiracetam for the treatment of epilepsy among adults with intellectual disabilities. J Intellect Disabil Res 2007; 51: 564-565.
• 25 Diener HC. et al. Leitlinien für Diagnostik und Therapie in der Neurologie (Hrsg). Kommission “Leitlinien der Deutschen Gesellschaft für Neurologie”. Stuttgart: Thieme; 2008
• 26 Donati F. et al. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. 2006; 67: 679-682.
• 27 Ettinger A. et al. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998; 39: 874-877.
• 28 Fröscher W. Indikationen zur Bestimmung der Antiepileptika-Serumkonzentration. In: Fröscher W, Blankenhorn V, May Th W. et al. Pharmakotherapie der Epilepsien, 4. Aufl. Stuttgart: Schattauer; 2008: 252-260.
• 29 Fröscher W. Laborwertveränderungen durch Antiepileptika. In: Fröscher W, Blankenhorn V, May Th W. et al. Pharmakotherapie der Epilepsien, 4. Aufl. Stuttgart: Schattauer; 2008: 221-260.
• 30 Fröscher W. et al. Topiramate: Prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 2005; 237-248.
• 31 Gaily E, Granstom ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl. 01) 41-45.
• 32 Gillberg C, Soderstrum H. Learning disability. Lancet 2003; 362: 811-821.
• 33 Gleissner U. et al. Postsurgical outcome in pediatric patients with epilepsy: a comparison of patients with intellectual disabilities, subaverage intelligence, and average-range intelligence. Epilepsia 2006; 47: 406-414.
• 34 Hannah JA, Brodie MJ. Epilepsy and learning disabilities – a challenge for the next millennium?. Seizure 1998; 07: 3-13.
• 35 Helmstaedter C. et al. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 2008; 13: S35-S41.
• 36 Hitiris N, Mohanraj R, Norrie J. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75: 192-196.
• 37 Huber B. Effects of topiramate in patients with epilepsy and intellectual deficits. Nervenarzt 2002; 73: 525-532.
• 38 Huber B. Die neuen Antiepileptika in der Epilepsiebehandlung von Patienten mit geistiger Behinderung. Z Epileptol 2004; 17: 257-269.
• 39 Huber B. et al. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure 2004; 13: 168-175.
• 40 Huber B. et al. Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability. Epilepsy Behav 2008; 13: 397-401.
• 41 Huber B. et al. Seizure freedom with different therapeutic regimens in intellectualy disabled epileptic patients. Seizure 2005; 14: 381-386.
• 42 Huber B. et al. Long-term course of epilepsy in a large cohort of intellectually disabled patients. Seizure 2007; 16: 35-42.
• 43 Huber B, May Th, Seidel M. Lamotrigine in multihandicapped therapy-resistant epileptic patients. Clin Drug Invest 1998; 16: 263-277.
• 44 Huber B, Tomka-Hoffmeister M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure 2003; 12: 602-603.
• 45 Huttenlocher PR, Hapke JR. A follow-up study of intractable seizures in childhood. Ann Neurol 1990; 28: 699-705.
• 46 Jones RSP, Vaughan FL, Roberts M. Mental retardation and memory for spatial locations. Am J Ment Retard 2002; 107: 99-104.
• 47 Kelly K, Stephen LJ, Brodie MJ. Pharmacological outcomes in people with mental retardation and epilepsy. Epilepsy Behav 2004; 05: 67-71.
• 48 Kerr M, Beavis J, Meek A. A multicentre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities. Program No. 3.193., Abstract Viewer. Philadelphia, PA: American Epilepsy Society; 2007
• 49 Khurana DS. et al. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996; 128: 829-833.
• 50 Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Pediatr Neurol 2008; 12: 19-23.
• 51 Krämer G. et al. Expert opinion on treatment of epilepsy in Germany, Austria and Switzerland for adults 2007. Program No. 3. 199. Abstract Viewer. Philadelphia, PA: American Epilepsy Society; 2007
• 52 Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiat 1997; 62: 372-376.
• 53 Maganti R, Gidal BE, Show R, Rutecki P. Concomitant use of divalproex sodium and lamotrigine in developmentally disabled patients with epilepsy: a retrospective evaluation of efficacy and tolerability. Epilepsy Behav 2002; 03: 275-279.
• 54 Marson AG. et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000-1015.
• 55 Marson AG. et al. The SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.
• 56 McCabe PH. Impact of the new AEDs in cognitively impaired patients with intractable epilepsy. Program No. 3.226. Abstract Viewer. Philadelphia, PA: American Epilepsy Society; 2007
• 57 McKee JR. et al. Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. J Child Neurol 2006; 21: 372-379.
• 58 Mikati MA. et al. Gabapentin in the treatment of refractory partial epilepy in children with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl. 01) 57-62.
• 59 Milteer W, Modus PN. Adjuncitve pregabaline in mentally retarded, developmentally disabled patients with epilepsy. Program No. 3.184. Abstract Viewer. Philadelphia, PA: American Epilepsy Society; 2007
• 60 Modur PN, Milteer WE. Adjunctive pregabalin therapy in mentally retarded developmentally delayed patients with epilepsy. Epilepsy Behav 2008; 13: 54-556.
• 61 Mohanraj R. et al. Clinical experience with levetiracetam: a prospective observational study. Epilepsia 2002; 43 (Suppl. 07) 196-197.
• 62 Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 04: S25-S38.
• 63 Nakken KO, Eriksson A-S, Lossius R, Johannessen SI. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003; 12: 42-46.
• 64 Neher K-D. Interaktionen: Beeinflussung der Serumkonzentration von Antiepileptika durch andere Medikamente. In: Fröscher W, Blankenhorn V, May Th W. et al. Pharmakotherapie der Epilepsien, 4.Aufl. Stuttgart: Schattauer; 2008: 135-177.
• 65 Neher K-D. Interaktionen: Beeinflussung der Serumkonzentration von Nichtantiepileptika durch Antiepileptika. In: Fröscher W, Blankenhorn V, May Th W. et al. Pharmakotherapie der Epilepsien, 4. Aufl. Stuttgart: Schattauer; 2008: 178-196.
• 66 Niedermeyer E. The Epilepsies. München: Urban und Schwarzenberg; 1990
• 67 Noachtar S, Hufnagel A, Winkler PA. Chirurgische Behandlung der Epilepsien. In: Brandt Th, Dichgans J, Diener H Ch. (Hrsg.) Therapie und Verlauf neurologischer Erkrankungen, 5. Aufl. Stuttgart: Kohlhammer; 2007: 224-238.
• 68 Opp J. et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476-848.
• 69 Paclawskyj TR. et al. Factor structure of the Matson evaluation of social skills for individuals with severe retardation (MESSIER). Br J Clin Psychol 1999; 38: 289-293.
• 70 Patsalos PN. et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
• 71 Poduri A. et al. Epilepsy surgery outcome is effected by presence of an MRI lesion, normal intelligence and history of prior surgery : The Children’s Hospital Boston Experience. Program No. 1.146. Abstract Viewer. Philadelphia, PA: American Epilepsy Society; 2007
• 72 Rating D, Fröscher W, Schulze-Bonhage A. Epilepsie-Bericht Baden-Württemberg 2004. Herausgeber: Landesärztekammer Baden-Württemberg, Stuttgart; 2005: S32.
• 73 Rösche J. et al. Der Einfluss antiepileptischer Polytherapie auf kognitive Funktionen und Stimmung. Z Epileptologie 2005; 18: 131.
• 74 Rosenfeld W. et al. Safety and tolerability of lacosamide: A summary of adverse events in epilepsy clinical trials. Program No. 3.245. 2008 Abstract Viewer. Seattle, WA: American Epilepsy Society.;
• 75 Saß H, Wittchen H-U, Zaudig M, Houben I. (Deutsche Bearbeitung und Einführung, 2003) DSM-IVTR. Diagnostisches und statistisches Manual psychischer Störungen – Testrevision. Hogrefe, Göttingen: 2003
• 76 Schmidt D. et al. Was tun, wenn das erste Medikament versagt?. Nervenheilkunde 2007; 26: 61-66.
• 77 Schneble H. Lennox-Gastaut-Syndrom. In: Fröscher W, Vasella F, Hufnagel A. (Hrsg). Die Epilepsien. Stuttgart: Schattauer; 2004: 167-274.
• 78 Shields WD. Management of epilepsy in mentally retarded children using the newer antiepileptic drugs, vagus nerve stimulation, and surgery. J Child Neurol 2004; 19 (Suppl. 01) S58-S64.
• 79 Simister RJ, Sander JW, Koepp MJ. Long-term retention of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 2007; 10: 336-339.
• 80 Singh BK. et al. Trial of pregabalin in adults with epilepsy and developmental disabilities. Program No. 1150. 2008 Abstract Viewer. Seattle, WA: American Epilepsy Society.;
• 81 Singh BK. White-Scott Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 2002; 11: 47-50.
• 82 Sirsi D, Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf 2007; 06: 241-250.
• 83 Steinhoff B. Nebenwirkungen der Antiepileptika. In: Fröscher W, Vasella F, Hufnagel A. (Hrsg). Die Epilepsien. Stuttgart: Schattauer; 2004: 564-602.
• 84 Szücs A. et al. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. Epilepsia 2008; 49: 1174-1179.
• 85 Vahar-Matiar M, Fröscher W. Die Osteopathia antiepileptica bei Jugendlichen und Erwachsenen. Fortschr Neurol Psychiatr 1988; 56: 216-230.
• 86 Vignoli A. et al. Efficacy and tolerability of levetiracetam in adult patients with mental retardation. Program No. 3.220. Abstract Viewer. Philadelphia, PA: American Epilepsy Society; 2007
• 87 Vimpat Fachinformation. UCB GmbH; Monheim: August 2008
• 88 Weintraub B. et al. Head to head comparison of the sedating effect of antiepileptic drugs in adults with epilepsy. Neurology 2005; 64 (Suppl. 01) A114.
• 89 Wernsheimer H. Testpsychologische Untersuchungen bei Erwachsenen mit Intelligenzminderung in der Psychiatrie. In: Schanze C. (Hrsg.). Psychiatrische Diagnostik und Therapie bei Menschen mit Intelligenzminderung. Stuttgart: Schattauer; 2007: 37-40.
• 90 Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008; 17: 405-421.
• 91 Ensrud KE. et al. Antiepileptic drug use and rates of hip bone loss in older men. Neurology 2008; 71: 723-730.